Generic Name: incobotulinumtoxin A
Brand Name: Xeomin
Manufacturer: Merz Pharmaceuticals GMBH
Therapeutic Area: Chronic sialorrhea associated with neurological disorders
Indications: For the treatment of chronic sialorrhea associated with neurological disorders in adults.
Manufacturer Requested Reimbursement Criteria1: For the treatment of chronic sialorrhea associated with neurological disorders in adults.
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Received
Companion Diagnostics: No
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
---|---|
Call for patient/clinician input open | January 28, 2021 |
Call for patient/clinician input closed | March 19, 2021 |
Submission received | February 26, 2021 |
Submission accepted | - |